CLAIMS

1. Compositions containing, as active ingredient, a mixture of amino acids consisting of glycine, L-proline, L-alanine, L-valine, L-leucine and L-lysine hydrochloride in the following weight ratios:

- Glycine 1;
- L-proline: 0.7-0.8;
- L-alanine: 0.47-0.76;
- L-valine: 0.35-0.56;
- L-leucine: 0.13-0.27;
- L-lysine hydrochloride: 0.10-0.12.

2. Compositions as claimed in claim 1, also containing L-cysteine or N-acetyl-L-cysteine in percentages by weight ranging between 1 and 20% of the total amino-acid mixture.

3. Compositions as claimed in claim 1 or 2 wherein the weight ratios of the amino acids are:

- Glycine 1;
- L-proline: 0.75;
- L-alanine: 0.48-0.51;
- L-valine: 0.35-0.37;
- L-leucine: 0.13-0.15;
- L-lysine hydrochloride: 0.10-0.11.

4. Compositions as claimed in claim 1 or 2 wherein the weight ratios of the amino acids are:

- Glycine 1;
- L-proline: 0.75;
- L-alanine: 0.75-0.76;
- L-valine: 0.54-0.56;
- L-leucine: 0.13-0.14;

- L-lysine hydrochloride: 0.10-0.11.

5. Compositions as claimed in claim 1 or 2 wherein the weight ratios of the amino acids are:

- Glycine 1;
- L-proline: 0.75;
- L-alanine: 0.49-0.51;
- L-valine: 0.35-0.36;
- L-leucine: 0.26-0.27;
- L-lysine hydrochloride: 0.10-0.11.

6. Compositions as claimed in any of the preceding claims for oral use.

7. Compositions as claimed in claim 6 in the form of solutions, granules, dispersible powder, tablets or capsules.

8. Compositions as claimed in any one of claims 1 to 5, also containing hyaluronic acid or salts thereof, in particular sodium hyaluronate, with an average molecular weight ranging between 500,000 and 3,000,000 Da, in percentages ranging between 0.01 and 3% by weight of the total composition.

9. Compositions as claimed in claim 8 for topical or injective use.

10. Compositions as claimed in claim 9 in the form of gels, ointments, emulsions, transdermal patches, sterile solutions or sterile amino-acid powders designed to be reconstituted with sterile aqueous solutions of hyaluronates.

11. Compositions as claimed in claims 1-10, for use in the treatment of elastosis and dermoepidermal atrophy resulting from photoaging, skin disorders with a dermoatrophic and iatrogenic cause, burns, radiation burns, skin lesions, bedsores, dermal aplasia caused by drug administration, tendon and joint lesions.

12. Use of compositions as claimed in claims 1-10 in the manufacture of a medicament for the treatment of elastosis and dermoepidermal atrophy resulting from photoaging, skin disorders with a dermoatrophic and iatrogenic cause, burns, radiation burns, skin lesions, bedsores, dermal aplasia caused by drug administration, tendon and joint lesions.